IGA nephropathy – Are intravenous steroid pulses more effective than oral steroids in relapse prevention? by Laranjinha, Ivo et al.
n e f r o l o g i a 2 0 1 8;3 8(4):427–432
www.rev is tanef ro logia .com
Revista de la Sociedad Española de Nefrología
Original article
IGA  nephropathy  – Are  intravenous  steroid  pulses  more
effective than  oral  steroids  in relapse  prevention?
Ivo Laranjinhaa,b,∗, Patrícia Matiasa,b, João Cassis c, Patrícia Brancoa,b,  Sância Ramosc,
José  Diogo Barataa, André Weigerta,d
a Hospital de Santa Cruz, Nephrology Department, Lisbon, Portugal
b Nova Medical School, Faculdade de Ciências Médicas, Lisbon, Portugal
c Centro Hospitalar de Lisboa Ocidental, Pathology Department, Lisbon, Portugal
d University of Lisbon, Faculdade de Medicina, Lisbon, Portugal
a  r  t  i  c  l  e  i  n  f  o
Article history:
Received 19 April 2017
Accepted 8 August 2017





a  b  s  t  r  a c  t
Introduction: It is recommended that IgA nephropathy (IgAN) is treated with steroids when
the glomerular filtration rate (GFR) is >50 ml/min and proteinuria >1 g/day. Few studies have
been  performed comparing the two accepted steroid regimens (1 g/day methylprednisolone
pulses for 3 consecutive days at the beginning of months 1, 3 and 5, followed by 0.5 mg/kg
prednisolone on alternate days vs. 1 mg/kg/day oral prednisolone). The aim of this study
was  to compare these two steroid regimens in IgAN treatment.
Methods: We selected 39 patients with biopsy-proven IgAN treated with steroids. Mean age
at  diagnosis was 37.5 years, 23 males (59%), baseline proteinuria (Uprot) was 2.1 g/day and
median serum creatinine (SCr) was 1.5 mg/dl. The mean follow-up period was 56 months.
Twenty-five patients (64%) were treated with methylprednisolone pulses and 14 (36%) with
oral steroids.
Results: Patients treated with steroid pulses presented lower relapse risk, defined as the
reappearance of Uprot >1 g/day and an Uprot increase of more than 50% (incidence rate
ratio  of 0.18, 95% CI 0.02–0.5). The Kaplan–Meier analysis showed longer relapse-free period
(p  = 0.019). This result was confirmed in a multivariate analysis (p = 0.026). However, we  did
not  find other differences between the two steroid regimens.
Conclusions: In comparison to oral steroids, the intravenous pulse regimen was associated
with a lower risk of relapse in IgAN, a known independent negative predictor of renal
survival. No differences were found regarding the other renal outcomes.
©  2017 Sociedad Española de Nefrologı́a. Published by Elsevier España, S.L.U. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
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Nefropatía  por  IgA.  ¿Son  los  esteroides  intravenosos  más  eficaces  que  los





r  e  s  u  m  e  n
Introducción: Se recomienda el tratamiento de la nefropatía por IgA (NIgA) con esteroides
cuando el índice de filtración glomerular (IFG) > 50 ml/min y proteinuria > 1 g/día. Pocos han
sido  los estudios realizados comparando los 2 esquemas de esteroides aceptados (1 g/día de
metilprednisolona en pulsos durante 3 días consecutivos en el principio de los meses 1, 3 y 5
seguido de 0,5 mg/kg en días alternos de prednisolona vs. 1 mg/kg/día de prednisolona oral).
El  objetivo de este estudio fue comparar estos 2 esquemas de esteroides en el tratamiento
de  la NIgA.
Métodos: Fueron seleccionados 39 pacientes con NIgA demostrada por biopsia y tratados
con  esteroides. La edad media al diagnóstico fue de 37,5 años, 23 varones (59%), proteinuria
basal (Uprot) 2,1 g/día y la creatinina sérica mediana (SCR) 1,5 mg/dl. El periodo medio de
seguimiento fue de 56 meses. Veinticinco de los pacientes (64%) fueron tratados con pulsos
de  metilprednisolona y 14 (36%) con esteroides orales.
Resultados: Los pacientes tratados con pulsos de esteroides presentan menor riesgo de
recaída, definido como la reaparición de una Uprot > 1 g/día y aumento de más  del 50%
de  la Uprot (razón de tasa de incidencia: 0,18; IC 95%: 0,02-0,5) y el Kaplan-Meier mostró
período más  largo libre de recaída (p = 0,019). Este resultado se confirmó en un análisis mul-
tivariante (p = 0,026). Sin embargo, no se encontraron otras diferencias entre los esquemas
de  esteroides.
Conclusiones: En comparación con los esteroides orales, el esquema en pulsos intravenosos
se  relacionó con un menor riesgo de recaída en la NIgA, un conocido predictor negativo
independiente de la supervivencia renal. No se encontraron diferencias en cuanto a los
otros outcomes renales.
© 2017 Sociedad Española de Nefrologı́a. Publicado por Elsevier España, S.L.U. Este es un
artı́culo Open Access bajo la licencia CC BY-NC-ND (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
Introduction
IgA nephropathy (IgAN) is the most frequent primary
glomerulonephritis in the developed countries. Regardless
of the treatment used, more  than 50% of the patients with
IgAN have a progressive disease.1 The VALIGA cohort esti-
mated a rate of glomerular filtration ratio (GFR) decline of
1.8 ± 7.5 ml/min/year.2 Therefore, it is predictable that 20–40%
of these patients develop end-stage renal disease (ESRD)
within 20 years.3
Currently there is not a specific treatment for the
pathogenic process beyond IgAN. The KDIGO guidelines4
recommend blood pressure control with the use of one
renin–angiotensin system inhibitor/blocker in all patients.
This approach has the stronger evidence in slowing the dis-
ease progression and reducing the proteinuria and the slope
of GFR.4,5
Besides these measures, with a significantly lower evi-
dence, this guidelines also suggest the use of corticosteroids
for 6 months in those that have proteinuria higher than
1 g/day and preserved GFR (GFR > 50 ml/min) after supportive
therapy.4 The treatment with steroids was associated with
lower risk of progression to ESRD and lower urinary protein
excretion.6
There are two steroid regimens accepted to treat IgAN:
the steroid pulse regimen (also known as “Pozzi scheme”, i.e.
1 g/day methylprednisolone pulses for 3 consecutive days at
the beginning of months 1, 3 and 5 followed by 0.5 mg/kg of
oral prednisolone in alternate days) and the oral steroid regi-
men  (oral prednisolone 1 mg/kg/day for 2 months and then a
reduced dose for the next 4 months).4 According to the avail-
able studies any of these therapeutic schemes can be used,
because both showed to be better than supportive therapy
alone.7–9
Currently, we do not have any reason to choose one steroid
scheme to treat IgAN instead of the other, as no RCT compared
both regimens, so this choice is only based on the beliefs of
the physicians and it is not an evidence-based decision. Since
the use of pulses scheme is more  laborious and expensive it
is important to clarify whether its use is associated with bet-
ter renal outcomes relatively to the simpler and cheaper oral
scheme.
The aim of this study was to investigate if there is any
advantage of a steroid pulse regimen relatively to oral steroid
scheme in the outcomes of the IgAN treatment.
Study  design
This is a single center, 9-year retrospective cohort
study of patients with biopsy-proven IgAN treated with
steroids.
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Table 1 – Baseline characteristics of the studied population.
Variables Patients (n = 39) Oral steroids (n = 14) Steroid pulses (n = 25) p
Age, years 37.5 ± 1.8 36.7 ± 9.1 37.9 ± 12.3 0.332
Gender, male 23 (59.0) 10 (71.4) 13 (56.5) 0.410
Race, black 2 (5.1) 1 (7.1) 1 (4.0) 0.811
Cumulative prednisolone-equivalent steroids dose, g 14.1 (6.1–14.4) 6 (5.4–7.2) 14.3 (14.1–14.6) <0.001
Hypertension (HTN) 18 (46.2) 5 (35.7) 13 (52.0) 0.121
Smoke 7 (17.9) 5 (55.6) 2 (16.7) 0.102
Proteinuria, g/day 2.1 (1.5–3.8) 3.1 (1.1–5.5) 2.0 (1.6–3.6) 0.139
GFR, ml/min 53 (31–74) 41 (14.3–78.8) 54 (39.5–71.5) 0.160
History of macroscopic hematuria 8 (20.5) 3 (21.4) 5 (20) 0.901
Microscopic hematuria 32 (82.1) 10 (71.4) 22 (88) 0.408
Serum albumin, g/dl 3.5  ± 0.6 3.4 ± 0.7 3.6 ± 0.5 0.792
Serum total cholesterol, mg/dl 220.7 ± 56.0 233.4 ± 82.0 214.1 ± 36.9 0.430
Follow-up, months 56 (24–104) 51(12–90.5) 56 (31–104) 0.761
Person-time, months 2578 808 1770 <0.001
Histological grade – Oxford classification
Mesangial cellularity (M1) 29 (85.3) 11 (91.7) 18 (81.8) 0.419
Segmental glomerulosclerosis (S1) 13 (38.2) 3 (25) 10 (45.5) 0.321
Endocapillary hypercellularity (E1) 19 (55.9) 9 (75) 10 (45.5) 0.157
Tubular atrophy/interstitial fibrosis (T1/T2) 27 (79.4) 8 (66.6) 19 (86.3) 0.693
Values are: mean ± SD, median (interquartile range) or frequencies [n (%)].
Subjects  and  methods
We  selected 62 patients with primary IgAN, who had been
biopsied between January 2006 and December 2014, from these
only 39 were eligible for the study. The inclusion criteria
were: having proteinuria greater than 1 g/day after at least
6 months of treatment with angiotensin-converting enzyme
inhibitors (ACE-I) and/or angiotensin receptor blockers (ARB)
before steroids, having received at least 6 months of steroid
therapy (pulse or oral regimen), age > 18 years at diagnosis and
follow-up duration > 12 months. All the patients included in
the study were under RAAS blockage for at least 6 months.
The doses were titrated upward as far as tolerated by each
patient.
The exclusion criteria were: pregnancy, chronic advanced
liver disease, presence of Henoch–Schonlein purpura or atyp-
ical forms of IgAN (acute kidney injury or crescentic IgAN).
Clinical information concerning demographic, clinical and
laboratory data were collected from the clinical process. For
the purpose of this study all the kidney biopsies were reviewed
and classified according to Oxford classification by the same
kidney pathologist.
Complete remission was defined as a protein-
uria < 0.3 g/day without worsening of renal function at
the end of steroid therapy (6 months). Partial remission was
defined as at least a 50% reduction in proteinuria compared
with baseline after 6 months of therapy.
Relapse was defined as the recurrence of protein-
uria > 1 g/day and at least a 50% increase in proteinuria
compared to the lowest proteinuria achieved after treatment.
Our endpoints were a combined endpoint of doubling
serum creatinine (SCr) or ESRD, rate of complete or partial
remission, GFR decline rate and relapse rate.
According to the type of steroid regimen used the patients
were divided in two groups: pulse steroid group (n = 25, 64%)
and oral steroid group (n = 14, 36%).
The cumulative prednisolone-equivalent steroids dose (in
grams) was  obtained by multiplying the dose per day (pill or
injection) by the prednisolone conversion factors, then multi-
plying it by the number of days of treatment.
Statistical  analysis
Variables are expressed as frequencies for categorical vari-
ables, mean values with SD for continuous variables and
median values with interquartile ranges for ordinal variables.
Comparison between groups was performed using T-test
for normally distributed variables, Wilcoxon test for non-
normally distributed variables and 2 test for categorical
variables. Survival curves were estimated by Kaplan–Meier
analysis and compared by the log-rank test. Cox regression
analysis was used for multivariable analysis.
Statistical analysis was performed with SPSS system 21.0
(SPSS Inc., Chicago, IL). For all comparisons, a p < 0.05 was con-
sidered statistically significant.
Results
A total of 39 biopsy-proven IgAN patients were included in
the study. Their baseline demographic, clinical and laboratory
characteristics are summarized in Table 1. Of the studied pop-
ulation 59% were male, mean age was 37.5 years, 94.9% were
caucasian and had a median follow-up time of 56 months after
treatment.
The baseline characteristics in both groups were simi-
lar concerning to age, gender, hypertension prevalence, GFR,
urinary protein excretion, micro and macroscopic hema-
turia and serum albumin (Table 2). Regarding the renal
biopsies, we  found that the four parameters of the Oxford
classification were also similar between groups. The cumu-
lative prednisolone-equivalent steroids dose was significantly
higher in the group of pulses regimen (14.3 vs. 6 g, p < 0.001).
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Table 2 – Univariate analysis for the development of the main outcomes and side effects.
Oral steroids (n = 14) Steroid pulses (n = 25) IRR (confidence interval) p
Doubled SCr or ESRD 3 (21.4%) 8 (32%) 1.22 0.507
Incidence ratea 3.7 (1.2–11.5) 4.5 (2.2–9.0) (0.29–7.12)
GFR decline rate, ml/min/year −4.0  ± 6.3 −4.5  ± 8.0 0.729
GFR at the end of the follow-up, ml/min 54.2  (34.5–97.6) 45.7 (26.9–66.3) 0.430
Complete or parcial remission 9 (75%) 20 (80%) 0.810
Relapse 5 (35.7%) 2 (8.0%) 0.18 0.044
Incidence ratea 6.2 (2.6–14.9) 1.1 (0.3–4.5) (0.018–0.85)
Microscopic hematuria at the end of
the follow-up
5  (35.7) 5 (20) 0.46 0.231
2.8 (1.25–7.1) 6.1 (3.01–13.2) (0.11–1.98)
Median proteinuria, g/day
At 6 months (end of treatment) 0.3 (0.1–1.2) 0.4 (0.2–1.2) 0.903
At 12 months 0.2 (0.1–0.3) 0.4 (0.1–0-9) 0.894
At 36 months 0.2 (0.1–0.4) 0.5 (0.1–1.1) 0.920
At 60 months 0.3 (0.2–0.6) 0.3 (0.1–1.4) 0.997
Proteinuria < 0.3 g/day
At 6 months (end of treatment) 7 (50%) 9 (36%) 0.410
At 12 months 8 (80%) 10 (47.6%) 0.120
At 36 months 5 (71.4%) 7 (38.9%) 0.328
At 60 months 4 (66.7%) 5 (45.5%) 0.548
Side effects of steroids
De novo or worsening diabetes 2 (14.3%) 2 (8%)
Incidence ratea 0.003 (0.0006–0.009) 0.001 (0.003–0.005) 0.46 (0.03–6.3) 0.790
Cushingoid state 1 (7.1%) 2 (8%)
Incidence ratea 0.006 (0.0008–0.004) 0.0025 (0.0006–0.009) 0.23 (0.004–4.4) 0.510
HR, hazard ratio; IRR, incidence rate ratio.
Values are: mean ± SD, median (interquartile range) or frequencies [n (%)].
a Incidence rate presented by cases/1000 person-months (95% confidence interval).
During the follow-up period, 8 patients in the group of
steroid pulse regimen and 3 in the oral prednisolone regimen
reached the combined outcome of doubling SCr or ESRD, how-
ever this difference was not statistically significant (IRR 1.22,
95% CI 0.29–7.12). The mean GFR decline rate was also not
different between groups (steroid pulse – 4.5 ml/min/year vs.
steroid oral scheme – 4.0 ml/min/year).
In both groups, 75% or more  of the total patients achieved
partial or complete remission. On the other hand, the
patients treated with steroid pulses showed lower relapse rate
(incidence rate 1.1 vs. 6.2 relapses/person-months and an inci-
dence rate ratio of 0.18, 95% CI 0.02–0.85).
Kaplan–Meier analysis showed that the patients treated
with steroid pulse regimen had a longer period of time free
to relapse (Log Rank test = 5.505, p = 0.019) (Fig. 1). Cox regres-
sion analysis confirmed this result in a model adjusted to age
and baseline proteinuria (HR = 0.18, 95% CI 0.04–0.82, p = 0.026)
(Table 3).
The median urinary protein excretion decreased in both
groups soon after the treatment (at 6 months of follow-
up), and both groups maintained a similar urinary protein
excretion. Similarly, the proportion of patients that achieved
proteinuria lower than 0.3 g/day were comparable between the
two groups during the follow-up.
The survival analysis did not find steroid pulses as a sig-
nificant predictor for the other analyzed endpoints such as
achieving complete or partial remission.
Regardless of the higher cumulative prednisolone-
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Fig. 1 – The steroid pulse regimen was associated with
lower relapse rate in IgAN (Kaplan–Meier analysis). This
result was confirmed in a multivariable analysis (Cox
regression) adjusted to age and baseline proteinuria
(2 = 9.09, p = 0.028).
higher incidence of steroids side effects. There was not an
increased incidence of diabetes, cushingoid state or infec-
tions severe enough to require special medical care, such
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Table 3 – Predictors of time free of relapses (Cox regression).
Dependent variable Independent variable HR 95% CI p R2
IgAN
relapse
Age  0.94 0.82–1.07 0.371 5.83
Proteinuria 0.999 0.998–1.00 0.741
Steroid pulses 0.10 0.01–0.87 0.036
HR, hazard ratio; IRR, incidence rate ratio.
p = 0.019.
as antibiotic prescription (no cases reported), during the
follow-up (Table 2).
Discussion
In our cohort of patients, the IgAN treatment with steroid
pulse regimen was associated with a lower risk of relapses.
However, no significant differences were found regarding the
main renal outcomes, such as development of ESRD, eGFR
decline or remission rate.
It is well studied that the relapse rate was an independent
negative predictor of renal survival in patients with IgAN.10
In our study, the lower rate of relapses in the pulses steroid
group was not associated with a slower progression of the dis-
ease, evaluated by eGFR decline rate or incidence of ESRD. IgA
nephropathy is a glomerular disease with a slow progression
to ESRD. Different studies predicted that less than 50% of the
patients with IgAN will progress to ESRD in 20–25 years.3 We
believe that in order to evaluate long-term outcomes, such as
evolution to ESRD in IgAN, our cohort with a median follow-
up period of 56 months (4.6 years) is short. This can, at least
in part, explain why we did not found differences between
groups regarding ESRD development.
We found no differences between the two regimens
regarding to proteinuria reduction, remission achievement
after treatment or eGFR decline rate.
Only one study11 with 16 patients compared these two
regimens for the treatment of IgAN and found no significant
benefits of one scheme relatively to the other. However that
study has important limitations such as the fact that baseline
proteinuria was significantly different between groups and
the criteria used to treat IgAN patients with steroids (protein-
uria < 500 mg/day and SCr < 1.5 mg/dl) were different from the
current guidelines.4
Two main reasons have been presented to use high-
dose intravenous steroids followed by a moderate oral dose
instead of oral steroids alone in the treatment of many  kid-
ney and non-kidney diseases: firstly, the earlier and more
effective response, and secondly, the lower toxicity.12 The
administration of steroid pulse therapy achieves quicker and
stronger immunosuppressive and anti-inflammatory effects,
decreasing the needed dose of oral steroids in the main-
tenance therapy (which is associated to the most relevant
long-term adverse effects of the steroids, such as Cushing
syndrome, diabetes, osteoporosis, etc.) and avoiding the mor-
bidity associated with prolonged nephrotic syndrome.13 This
paradox, in which the administration of high-dose intra-
venous steroids is used to reduce the steroid-related side
effects, is based on studies where this regimen is as effec-
tive as the oral steroids in full-dose, but less toxic, in patients
with idiopathic nephrotic syndromes.14,15 On the other hand,
some clinical observations suggest that the immunosuppress-
ive effects of high dose of IV glucocorticoids occur too fast to be
explained only by the classic mechanism (genomic) of action,
suggesting that this high dose administration of steroids
has different pharmacologic effects than those produced
with lower doses.16 It was mainly observed in children with
steroid-resistant nephrotic syndrome, in which the admin-
istration of IV pulses of steroids lead to remission in some
cases.13,15 Nowadays there is some evidence that the cellular
effects of steroids are mediated by genomic and nongenomic
mechanisms.5,17
Coppo,18 reviewed the long-term beneficial or legacy effect
of IgAN treatment. “Legacy effect” is a term used to describe
the use of a treatment in an early phase of a disease that
can produce benefits long after the cessation of the interven-
tion. Some experiments suggests that it is possible to expect
a legacy effect of early treatments in IgAN, namely in younger
patients, with active and reversible pathology lesion, with nor-
mal  renal function.18 In IgAN, can we expect a superior legacy
effect using high intravenous steroid dose, which can produce
genomic and non-genomic effects?
In opposition to the Therapeutic Evaluation of Steroids
in IgA Nephropathy (TESTING) trial results, we  did not have
major steroid side effects, even in the group with IV pulses.
Patients treated with pulses regimen were exposed to a higher
dose of steroids than those treated with oral prednisolone,
however we did not find higher incidence of steroids side-
effects in these patients, such as diabetes or infections.
Likewise, the other study that compared the two regimens did
not find differences regarding side-effects.11 In the literature
we found studies evaluating similar steroid regimens in other
diseases which report equal or even less adverse effects19–21
and other studies reporting more  adverse effects22 with high-
dose pulse steroids.
The recent results of Supportive versus immunosuppress-
ive therapy of progressive IgA nephropathy (STOP) Trial23 and
the preliminary data from the TESTING Study5 forced us to
reflect again on the benefits in renal survival and adverse
effects of steroids in the treatment of IgAN. However, while
waiting for better designed and longer follow-up RCT there
is considerable cumulated evidence to support treating these
patients with ACE-I or ARB for at least 6 months and only
consider 6-month steroids therapy to try to delay the pro-
gression of the disease, when proteinuria higher than 1 g/day
persists.5
Our study has some limitations. It is a retrospective study,
so the choice between the regimens was made based on the
physician’s opinion, and we do not know the reasons why they
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choose one scheme over another. We also have a small cohort
of patients and the follow-up period is too short to evaluate
long-term outcomes.
Conclusions
Steroid pulses compared to oral pulse regimen can be associ-
ated with a lower risk of relapse in IgAN, a known independent
negative predictor of renal outcomes. However, this regimen
did not show advantage in other evaluated renal outcomes,
such as GFR decline rate, risk of doubling SCr or ESRD,
remission rate, proteinuria range or side effects. Random-
ized controlled studies are needed to confirm this results and
analyze if this potential benefit can improve the long-term
outcomes.
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